Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Low-fat Diet on Pyrotinib PK in Healthy Chinese Adults
NCT04315493Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Mar 2020
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of pyrotinib in HER2-positive breast cancer (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04315493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315493.